Literature DB >> 7666567

Rescue of vaccinia virus lacking the E3L gene by mutants of E3L.

H W Chang1, L H Uribe, B L Jacobs.   

Abstract

Vaccinia virus with the E3L gene deleted was able to replicate in RK-13 but not HeLa cells. This host range phenotype could be complemented by an E3L gene expressed transiently from a plasmid. Analysis of mutants of E3L indicates that the ability to complement deletion of E3L correlates with the ability of mutated proteins to bind double-stranded RNA but not with their ability to migrate to the nucleus.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7666567      PMCID： PMC189568     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  19 in total

1.  The complete DNA sequence of vaccinia virus.

Authors:  S J Goebel; G P Johnson; M E Perkus; S W Davis; J P Winslow; E Paoletti
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

2.  Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon.

Authors:  E Beattie; J Tartaglia; E Paoletti
Journal:  Virology       Date:  1991-07       Impact factor: 3.616

3.  Vaccinia-mediated rescue of encephalomyocarditis virus from the inhibitory effects of interferon.

Authors:  P Whitaker-Dowling; J S Youngner
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

4.  Characterization of a vaccinia virus-encoded double-stranded RNA-binding protein that may be involved in inhibition of the double-stranded RNA-dependent protein kinase.

Authors:  J C Watson; H W Chang; B L Jacobs
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

5.  Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase.

Authors:  K Carroll; O Elroy-Stein; B Moss; R Jagus
Journal:  J Biol Chem       Date:  1993-06-15       Impact factor: 5.157

6.  The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase.

Authors:  H W Chang; J C Watson; B L Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

7.  The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms.

Authors:  M V Davies; H W Chang; B L Jacobs; R J Kaufman
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

8.  Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms.

Authors:  S N Shchelkunov; V M Blinov; L S Sandakhchiev
Journal:  FEBS Lett       Date:  1993-03-15       Impact factor: 4.124

9.  The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2.

Authors:  M V Davies; O Elroy-Stein; R Jagus; B Moss; R J Kaufman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Vaccinia rescue of VSV from interferon-induced resistance: reversal of translation block and inhibition of protein kinase activity.

Authors:  P Whitaker-Dowling; J S Youngner
Journal:  Virology       Date:  1983-11       Impact factor: 3.616
View more
  54 in total

1.  A role for Z-DNA binding in vaccinia virus pathogenesis.

Authors:  Yang-Gyun Kim; Maneesha Muralinath; Teresa Brandt; Matthew Pearcy; Kevin Hauns; Ky Lowenhaupt; Bertram L Jacobs; Alexander Rich
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-30       Impact factor: 11.205

2.  Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins.

Authors:  José González-Santamaría; Michela Campagna; María Angel García; Laura Marcos-Villar; Dolores González; Pedro Gallego; Fernando Lopitz-Otsoa; Susana Guerra; Manuel S Rodríguez; Mariano Esteban; Carmen Rivas
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins.

Authors:  Jeffrey O Langland; John C Kash; Victoria Carter; Matthew J Thomas; Michael G Katze; Bertram L Jacobs
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  The identification and characterization of a monoclonal antibody to the vaccinia virus E3 protein.

Authors:  Jessica R Weaver; Mohammad Shamim; Edward Alexander; D Huw Davies; Philip L Felgner; Stuart N Isaacs
Journal:  Virus Res       Date:  2007-06-20       Impact factor: 3.303

5.  Loss of protein kinase PKR expression in human HeLa cells complements the vaccinia virus E3L deletion mutant phenotype by restoration of viral protein synthesis.

Authors:  Ping Zhang; Bertram L Jacobs; Charles E Samuel
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

Review 6.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

7.  Binding and relocalization of protein kinase R by murine cytomegalovirus.

Authors:  Stephanie J Child; Adam P Geballe
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination.

Authors:  Garilyn M Jentarra; Michael C Heck; Jin Won Youn; Karen Kibler; Jeffrey O Langland; Carole R Baskin; Olga Ananieva; Yung Chang; Bertram L Jacobs
Journal:  Vaccine       Date:  2008-04-08       Impact factor: 3.641

9.  Regulated, stable expression and nuclear presence of reovirus double-stranded RNA-binding protein sigma3 in HeLa cells.

Authors:  Z Yue; A J Shatkin
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections.

Authors:  Elena Domingo-Gil; Eva Pérez-Jiménez; Iván Ventoso; José L Nájera; Mariano Esteban
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.